Human-induced pluripotent stem cells (hiPSCs) can differentiate into various tissues, an invaluable characteristic for personalized regenerative medicine, basic and translational research, and drug ...

Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...

A team linked to Harvard Medical School has dosed the first patient in a clinical trial designed to reverse cellular aging in ...

A groundbreaking human trial of ER-100, a cellular reprogramming therapy, has begun, testing whether damaged eye cells can be rejuvenated and potentially opening a new chapter in the science of aging.

Researchers from Monash University in Melbourne and The University of Western Australia have demonstrated how a reprogramming method imitates embryonic epigenetic reset. Transient naive treatment (TNT ...

Zhou’s study, "TBX20 improves contractility and mitochondrial function during direct human cardiac reprogramming," was recently published in Circulation. The most common cause of death worldwide is ...